MBX
What one share of MBX Biosciences holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development.
MBX Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.41 |
|---|---|
| Capex (buildings and equipment) | $0.06 |
| Free cash flow | −$1.96 |
| Cash and investments | $8.73 |
| Book value | $8.54 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$31.96 | $0.13 | −$31.52 | — | −$57.65 |
| 2024 | — | −$5.82 | $0.08 | −$5.22 | — | — |
| 2025 | — | −$2.38 | $0.05 | −$2.24 | — | $8.22 |